BioVector? WM1799 人皮膚黑色素瘤細(xì)胞系 / BioVector? WM1799 Human Skin Melanoma Cell Line

通用定義 / General Definition:BioVector? WM1799 是一種源自人皮膚黑色素瘤 (Melanoma) 的原發(fā)性腫瘤細(xì)胞系。該細(xì)胞系處于黑色素瘤發(fā)展的徑向生長(zhǎng)期 (Radial Growth Phase, RGP)。在黑色素瘤的演進(jìn)過程中，RGP 代表了早期階段，此時(shí)腫瘤主要局限于表皮層內(nèi)向水平方向擴(kuò)張。WM1799 特別具有科研價(jià)值，因?yàn)樗鼣y帶 NRAS Q61L 突變，且其 BRAF 動(dòng)基因?yàn)橐吧?(WT)。這使其成為研究非 BRAF 突變型黑色素瘤發(fā)病機(jī)制、NRAS 驅(qū)動(dòng)的信號(hào)傳導(dǎo)通路以及開發(fā)針對(duì)性靶向療法的關(guān)鍵模型。

BioVector? WM1799 is a human skin Melanoma cell line derived from a primary tumor. It represents the Radial Growth Phase (RGP) of melanoma development. In the progression of melanoma, the RGP signifies an early stage where the tumor expands horizontally, primarily confined to the epidermis. WM1799 is particularly valuable for research as it carries the NRAS Q61L mutation while being BRAF Wild-Type (WT). This makes it a critical model for studying the pathogenesis of non-BRAF mutated melanoma, NRAS-driven signaling pathways, and the development of targeted therapies for this specific genetic subgroup.

BioVector? WM1799 技術(shù)說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? WM1799 人皮膚黑色素瘤細(xì)胞

• 組織來源： 皮膚 (Skin)

• 疾病背景： 黑色素瘤 (原發(fā)灶，徑向生長(zhǎng)期)

• 生長(zhǎng)特性： 貼壁生長(zhǎng)

• 細(xì)胞形態(tài)： 上皮樣或紡錘形，具有黑色素瘤早期的形態(tài)特征。

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? W489 培養(yǎng)基 或 MCDB153/L15 (4:1) 混合培養(yǎng)基。

• 血清添加： 2% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)。

• 關(guān)鍵添加劑： 5 $\mu$g/mL 胰島素 (Insulin)。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% CO2

• 傳代比例： 1:2 至 1:3；由于 RGP 期細(xì)胞生長(zhǎng)相對(duì)緩慢，建議在細(xì)胞匯合度達(dá)到 85% 時(shí)進(jìn)行傳代。

3. 細(xì)胞應(yīng)用

• 突變特異性研究： 探索 NRAS Q61L 突變對(duì) PI3K/Akt 和 MAPK 通路的特異性激活作用。

• 早期演變模擬： 研究黑色素瘤從徑向生長(zhǎng)期向垂直生長(zhǎng)期 (VGP) 轉(zhuǎn)化的分子開關(guān)。

• 藥物篩選： 篩選針對(duì) NRAS 突變型黑色素瘤的 MEK 抑制劑或聯(lián)合用藥方案。

4. 注意事項(xiàng)

• 生長(zhǎng)周期： 相比于晚期黑色素瘤細(xì)胞系（如 WM88），WM1799 的倍增時(shí)間可能較長(zhǎng)，需耐心維護(hù)。

• 基因組穩(wěn)定性： NRAS 突變是其核心特征，建議在實(shí)驗(yàn)關(guān)鍵節(jié)點(diǎn)通過測(cè)序確認(rèn)突變狀態(tài)。

English Datasheet

1. General Product Information

• Product Name: BioVector? WM1799 Human Skin Melanoma Cell Line

• Tissue Source: Skin

• Disease Context: Melanoma (Primary tumor, Radial Growth Phase)

• Growth Properties: Adherent

• Morphology: Epithelial-like or spindle-shaped, reflecting early-stage melanoma morphology.

2. Culture Conditions

• Basal Medium: BioVector? W489 Medium or MCDB153/L15 (4:1) mixture.

• Serum Supplement: 2% BioVector? Fetal Bovine Serum (FBS).

• Supplements: 5 $\mu$g/mL Insulin.

• Incubation: 37 degrees Celsius, 5% CO2.

• Subculturing: 1:2 to 1:3 ratio; as RGP cells typically proliferate more slowly, subculture when cells reach 85% confluence.

3. Applications

• Mutation-Specific Research: Exploring the specific activation of PI3K/Akt and MAPK pathways by the NRAS Q61L mutation.

• Early Progression Modeling: Investigating the molecular "switches" involved in the transition from Radial Growth Phase to Vertical Growth Phase (VGP).

• Drug Discovery: Screening MEK inhibitors or combination therapies specifically for NRAS-mutant melanoma subtypes.

4. Key Usage Notes

• Proliferation Rate: Compared to advanced melanoma lines (like WM88), WM1799 may have a longer doubling time; consistent monitoring is required.

• Genomic Integrity: The NRAS mutation is a defining characteristic; BioVector? recommends verifying the mutation status via sequencing at critical experimental junctures.

注意 / Note: BioVector? WM1799 應(yīng)在生物安全二級(jí) (BSL-2) 條件下操作。為保持其早期生長(zhǎng)期表型，建議避免使用高濃度血清。

BioVector? WM1799 should be handled under Biosafety Level 2 (BSL-2) conditions. To maintain its early growth phase phenotype, BioVector? advises against the use of high-concentration serum.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

E-mail: [email protected]

http://www.nedfriskphoto.com